Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETNA: Neoadjuvant Nab-paclitaxel in HER2-negative Breast Cancer
NCT01822314Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Apr 2013
- Primary completion
- Sep 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of nab-paclitaxel in breast cancer (2 arms), sponsored by Michelangelo Foundation. Primary endpoint: Pathologic Complete Response at 40 months. Started Apr 2013; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01822314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822314.